Skip to content

Vertex Pharmaceuticals Inc Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: November 2, 2026 results vs estimates

Vertex Pharmaceuticals Inc · E.VRTX.NASDAQ · United States
Use symbol E.VRTX.NASDAQ in our API & Excel add-in to retrieve this data ↓
540.00
(+0.02%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 100%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 28.57%

Vertex Pharmaceuticals Inc Forecast

Vertex Pharmaceuticals Inc short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 28.6% a year, a typical one-standard-deviation range is 518.27–561.73 over a week, 495.46–584.54 over a month and 385.70–694.30 over a year. (Signals as of 1 Nov 2026.)

Vertex Pharmaceuticals Inc Price Chart

MacroFinance.ai

Vertex Pharmaceuticals Inc Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Vertex Pharmaceuticals Inc
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Vertex Pharmaceuticals Inc
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Vertex Pharmaceuticals Inc
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Vertex Pharmaceuticals Inc
P/E
34.66x
Stretched vs own history
QoQ +9.0%
YoY +15.9%
now 34.660825.39 low35.12 high
ⓘP/E As of 22 Nov 2026.See Vertex Pharmaceuticals Inc returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
Vertex Pharmaceuticals Inc
P/S
10.64x
Mid-range vs own history
QoQ −4.4%
YoY +13.5%
now 10.64029.02 low11.35 high
ⓘP/S As of 22 Nov 2026.See Vertex Pharmaceuticals Inc returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Vertex Pharmaceuticals Inc
P/B
6.59x
Mid-range vs own history
QoQ −4.8%
YoY +3.8%
now 6.59145.69 low7.11 high
ⓘP/B As of 22 Nov 2026.See Vertex Pharmaceuticals Inc returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Vertex Pharmaceuticals Inc
EV/EBITDA
28.48x
Mid-range vs own history
QoQ +14.2%
YoY +25.8%
now 28.479519.9 low28.85 high
ⓘEV/EBITDA As of 22 Nov 2026.See Vertex Pharmaceuticals Inc returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Vertex Pharmaceuticals Inc
EV/Sales
10.65x
Mid-range vs own history
QoQ −0.1%
YoY +18.4%
now 10.65378.59 low10.89 high
ⓘEV/Sales As of 22 Nov 2026.See Vertex Pharmaceuticals Inc returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Vertex Pharmaceuticals Inc
FCF Yield
2.3%
Mid-range vs own history
QoQ −14.2%
YoY −23.5%
now 2.32372.29 low3.37 high
ⓘFCF Yield As of 22 Nov 2026.See Vertex Pharmaceuticals Inc returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Vertex Pharmaceuticals Inc
Earnings Yield
2.9%
Mid-range vs own history
QoQ −8.2%
YoY −13.7%
now 2.88512.85 low3.94 high
ⓘEarnings Yield As of 22 Nov 2026.See Vertex Pharmaceuticals Inc returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Vertex Pharmaceuticals Inc
Market Cap
$137.8B
Highest in 5 years
QoQ −1.7%
YoY +25.4%
now 137808108,566 low142,906 high
ⓘMarket Cap As of 22 Nov 2026.See Vertex Pharmaceuticals Inc returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Vertex Pharmaceuticals Inc
Net Debt
$175M
High vs own history
QoQ −103.0%
YoY −103.9%
now 175.1-5,875 low175.1 high
ⓘNet Debt As of 22 Nov 2026.See Vertex Pharmaceuticals Inc returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Vertex Pharmaceuticals Inc
Net Debt / EBITDA
0.04x
High vs own history
QoQ −103.3%
YoY −103.8%
now 0.0361-1.09 low0.04 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Vertex Pharmaceuticals Inc returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Vertex Pharmaceuticals Inc
Current Ratio
2.34x
Weak vs own history
QoQ −26.6%
YoY −1.0%
now 2.33712.34 low3.19 high
ⓘCurrent Ratio As of 22 Nov 2026.See Vertex Pharmaceuticals Inc returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Vertex Pharmaceuticals Inc
Quick Ratio
1.89x
Weak vs own history
QoQ −31.0%
YoY −5.5%
now 1.88811.89 low2.74 high
ⓘQuick Ratio As of 22 Nov 2026.See Vertex Pharmaceuticals Inc returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Vertex Pharmaceuticals Inc
Debt / Equity
0.31x
High vs own history
QoQ +217.3%
YoY +192.5%
now 0.30990.1 low0.31 high
ⓘDebt / Equity As of 22 Nov 2026.See Vertex Pharmaceuticals Inc returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Vertex Pharmaceuticals Inc
Piotroski F-Score
3
Mid-range vs own history
QoQ −40.0%
YoY −62.5%
now 33 low8 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Vertex Pharmaceuticals Inc returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Vertex Pharmaceuticals Inc
Altman Z-Score
8.8
Weak vs own history
QoQ −37.0%
YoY −18.5%
now 8.80128.48 low14.21 high
ⓘAltman Z-Score As of 22 Nov 2026.See Vertex Pharmaceuticals Inc returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  19 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  19 members-only factors: Sloan Accruals, Cash-Earnings Gap, Days Sales in Receivables Index, Gross Margin Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Vertex Pharmaceuticals Inc, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Vertex Pharmaceuticals Inc fundamentals: income statement, balance sheet & cash flow

Vertex Pharmaceuticals Inc reported revenue of $12.00bn and net income of $3.95bn in FY2025, the year ended 31 December 2025 — revenue up 8.9% and net income up 838.1% on the prior year. Free cash flow was $3.19bn. These figures are as reported in the filings, not restated: 36 fiscal years and 147 quarters of history, back to December 1990. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$12.00bn
+8.9%
Net income
$3.95bn
+838.1%
Gross margin
86.24%
Free cash flow
$3.19bn
+504.1%
Net debt
-$3.05bn
Shares short (30 Oct 2026)
4.81m
3.38 days to cover
Vertex Pharmaceuticals Inc income statement, annual, as reported · USD billions unless stated
USD billionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue12.0011.029.878.937.57
Cost of revenue1.651.531.261.080.90
Gross profit10.359.498.617.856.67
Research & development3.913.633.162.663.05
Selling, general & admin.—6.09—0.890.84
Operating income4.17-0.233.834.312.78
EBITDA4.380.494.614.442.92
Interest expense0.010.030.040.050.06
Pre-tax income4.640.254.384.232.73
Income tax0.690.780.760.910.39
Net income3.95-0.543.623.322.34

Download Vertex Pharmaceuticals Inc fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.VRTX.NASDAQ&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 36 fiscal years and 147 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on Vertex Pharmaceuticals Inc

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Vertex Pharmaceuticals Inc Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Vertex Pharmaceuticals Inc; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How Vertex Pharmaceuticals Inc’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Vertex Pharmaceuticals Inc behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Vertex Pharmaceuticals Inc (United States)

Vertex Pharmaceuticals Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Vertex Pharmaceuticals Inc

Frequently asked questions

What is Vertex Pharmaceuticals Inc?
Vertex Pharmaceuticals Inc is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Vertex Pharmaceuticals Inc price?
The latest close is 540 (1 Nov 2026), +0.02% on the day. The price at the top of the page refreshes during the trading day.
Is Vertex Pharmaceuticals Inc in an uptrend?
As of 1 Nov 2026, short-term momentum is strongly positive (4 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Vertex Pharmaceuticals Inc?
20-day realised volatility is 28.6% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 8.2% over a month and 4.0% over a week.
What factors affect Vertex Pharmaceuticals Inc?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Vertex Pharmaceuticals Inc, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Vertex Pharmaceuticals Inc?
58 backtested tactical asset allocation strategies trade Vertex Pharmaceuticals Inc through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Vertex Pharmaceuticals Inc returns analysed?
The Statistical Distribution of Returns section shows the distribution of Vertex Pharmaceuticals Inc daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Vertex Pharmaceuticals Inc historical data?
In the Free historical data section of this page: the last 10 years of Vertex Pharmaceuticals Inc daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Vertex Pharmaceuticals Inc historical data (last 10 years)

Browse or instantly download the last 10 years of Vertex Pharmaceuticals Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.VRTX.NASDAQ&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-20515.02
2026-11-19520.66
2026-11-18536.45
2026-11-17534.2
2026-11-16537.79
2026-11-13538.6
2026-11-12542.62
2026-11-11547.03
2026-11-10547.89
2026-11-09550.87
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.